Table 3.
MSU crystals | No crystals | Hazard ratio (95 % CI) | |
---|---|---|---|
(events / person-years) | (events / person-years) | PS adjusted* | |
All | 46 / 1026 | 34 / 1009 | 0.86 (0.52–1.43) |
Age <60 | 14 / 698 | 4 / 577 | 1.31 (0.42–4.15) |
Age 60–79 | 15 / 240 | 20 / 370 | 0.79 (0.36–1.76) |
Age 80+ | 17 / 88 | 10 / 62 | 0.79 (0.31–1.97) |
Male | 40 / 951 | 31 / 896 | 0.82 (0.47–1.41) |
Female | 6 / 75 | 3 / 113 | 1.87 (0.33–10.57) |
No previous APTC | 30 / 950 | 24 / 958 | 0.92 (0.48–1.74) |
Only previous APTC | 16 / 76 | 10 / 51 | 0.73 (0.28–1.94) |
CKD 4 + 5 | 8 / 41 | 3 / 74 | 2.57 (0.57–11.55) |
CKD 3 | 18 / 190 | 11 / 164 | 1.24 (0.54–2.86) |
CKD 2 | 8 / 580 | 19 / 611 | 0.35 (0.13–0.89) |
CKD 1 | 10 / 163 | 1 / 131 | 3.72 (0.44–31.23) |
DM | 11 / 103 | 9 / 102 | 0.79 (0.28–2.23) |
No DM | 35 / 923 | 25 / 907 | 0.93 (0.51–1.69) |
Hypertension | 22 / 245 | 10 / 214 | 1.69 (0.76–3.78) |
Normotensive | 24 / 781 | 24 / 795 | 0.64 (0.32–1.26) |
APTC AntiPlatelet Trialists’ Collaboration, CI confidence interval, CKD chronic kidney disease stages, DM diabetes mellitus, MSU monosodium urate, PS propensity score
*All subgroups are PS adjusted. The no-crystal group was set as reference